Latest Ratios: P/E Ratio -14.9x · EV/EBITDA N/A · ROE -32.1%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $892M | $271M | $87M | — | — | — | — | — |
| Enterprise Value | $857M | $236M | $-3058 | — | — | — | — | — |
| P/E Ratio → | -14.86 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 5.53 | 1.69 | 0.41 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -32.1% | -32.1% | -46.3% | -29.7% | -30.6% | -50.3% | -98.0% | -31.8% |
| ROA | -31.1% | -31.1% | -45.1% | -28.6% | -29.4% | -48.0% | -89.8% | -30.6% |
| ROIC | -40.6% | -40.6% | -87.9% | -60.1% | -32.9% | -44.1% | -6678.2% | — |
| ROCE | -36.4% | -36.4% | -51.3% | -34.1% | -30.5% | -37.8% | -99.2% | -36.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.22 | -0.41 | -0.86 | -0.33 | -0.28 | -0.95 | -1.03 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($36M) exceeds total debt ($541000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.16 | 15.16 | 31.41 | 38.92 | 22.04 | 24.58 | 7.18 | 27.18 |
| Quick Ratio | 15.16 | 15.16 | 31.41 | 38.92 | 22.04 | 24.58 | 7.18 | 27.18 |
| Cash Ratio | 14.47 | 14.47 | 30.61 | 37.70 | 20.27 | 22.63 | 6.69 | 27.10 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $68M | $48M | $27M | $26M | $12M | $12M | $12M |
Binary clinical trial failure
According to current market data, CLYM trades at a price-to-book ratio of 5.53, which appears to reflect a significant premium over tangible assets, suggesting that investors are pricing in the potential future value of the budoprutug pipeline rather than the company's current, limited book value.
The absence of meaningful revenue or earnings renders traditional P/E and EV/EBITDA multiples irrelevant for assessing the company's fundamental value. Investors should monitor whether this valuation premium holds as the company approaches critical clinical data readouts, as any delay or negative result could lead to rapid multiple compression.
As reported in historical financial statements, CLYM's ROIC has consistently remained in negative territory, reaching a low of -103.8% in 2024Q2, which highlights the substantial capital destruction inherent in funding early-stage clinical development without any offsetting commercial revenue or licensing income.
The persistent negative returns on invested capital suggest that the company is currently in a value-consuming phase of its lifecycle. This trend warrants further investigation into whether the recent strategic pivot to budoprutug can eventually generate sufficient returns to justify the significant R&D capital deployed to date.
Based on recent quarterly filings, the company's current ratio has fluctuated significantly, dropping from a peak of 60.41 in 2024Q2 to 15.16 by 2025Q4, indicating a tightening liquidity position as the firm consumes its cash reserves to fund ongoing clinical trial activities.
While the current ratio remains numerically high, it is largely a function of the company's limited liabilities rather than operational strength. Investors should monitor the cash burn rate closely, as the current liquidity buffer may prove insufficient to reach the next major clinical milestone without additional dilutive financing.
As noted in industry analysis, the price-to-book ratio is frequently misapplied to clinical-stage biotechnology firms like CLYM, as it fails to capture the value of intangible R&D assets while simultaneously overstating the relevance of historical accounting costs in a pre-revenue, high-risk development environment.
Using P/B as a primary valuation metric obscures the binary nature of the company's clinical pipeline, where the true value is tied to the probability of regulatory success rather than the balance sheet. Analysts should instead focus on the cash-runway-to-milestone ratio to better gauge the company's operational viability.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLYM stock.
Climb Bio, Inc.'s current P/E ratio is -14.9x. This places it at the 50th percentile of its historical range.
Climb Bio, Inc.'s return on equity (ROE) is -32.1%. The historical average is -45.5%.
Based on historical data, Climb Bio, Inc. is trading at a P/E of -14.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.